Business Context and Reporting Period
This Form 6-K serves as an Annual Information Update for GlaxoSmithKline plc (GSK) covering the 12-month period ended March 23, 2012. The filing acts as a summary index of regulatory announcements, corporate filings, and shareholder documents published during the period, rather than a standalone financial report. GSK is a foreign issuer filing under Form 20-F.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This document functions as a reference list directing investors to other filings for detailed financial data. Key financial reports referenced include:
- Final Results: Announced on February 7, 2012.
- Annual Financial Report: Published on March 12, 2012.
- Annual Report 2011: Published on March 26, 2012.
- Quarterly Results: 1st Quarter (April 27, 2011), 3rd Quarter (October 26, 2011), and Half Yearly Report (August 2, 2011).
Material Changes and Corporate Actions
While specific financial variances are not detailed in this text, the following material corporate actions and strategic developments were announced during the period:
- Joint Venture: On March 2, 2012, GSK announced the formation of a joint venture with Daiichi Sankyo.
- Divestments: Updates were provided on the divestment of non-core Over-the-Counter (OTC) brands on December 20, 2011, and March 15, 2012.
- Acquisitions and Investments:
- Acquired a minority stake in Autifony Therapeutics (August 22, 2011).
- Purchased a stake in Shenzhen Neptunus (June 14, 2011).
- Notifiable share interests in Theravance, Inc. (May 4, August 3, and November 3, 2011) and OctoPlus N.V. (November 18, 2011).
- Shareholder Returns: Distribution of cash amounts on ordinary shares (February 16, 2012) and active share buy-back programs throughout the year.
- Legal Settlement: GSK reached a settlement with the US Government on November 3, 2011.
Guidance, Risks, and Unusual Items
The filing text does not provide specific forward-looking guidance, risk factors, or management commentary. However, it highlights the following items of note:
- Reporting Basis Change: On November 30, 2011, GSK announced it would report on a "core basis" starting from Q1 2012.
- Clinical Trials: Initial outcomes of Phase III studies for Relovair were announced on January 9, 2012.
- Regulatory Reviews: Blocklisting interim reviews were noted in May and November 2011.
- Board Changes: Changes to the Board were announced on January 27, 2012, with various director appointments and terminations filed throughout the year.
Investor Verification Checklist
- Review the Final Results (Feb 7, 2012) and Annual Report 2011 (Mar 26, 2012) for actual revenue, profit, and cash flow figures.
- Verify the financial impact of the US Government settlement announced in November 2011.
- Assess the strategic implications of the Daiichi Sankyo joint venture and the divestment of non-core OTC brands.
- Confirm the details of the new "core basis" reporting methodology effective Q1 2012.
- Check the status of the Relovair Phase III study outcomes for pipeline valuation.